Abraxis BioScience, Inc. – Product Pipeline Review – Q4 2010

Date: January 1, 2011
Pages: 81
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: AA38091946EEN
Leaflet:

Download PDF Leaflet

Abraxis BioScience, Inc. – Product Pipeline Review – Q4 2010
Abraxis BioScience, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Abraxis BioScience, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Abraxis BioScience, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Abraxis BioScience, Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Abraxis BioScience, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Abraxis BioScience, Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Abraxis BioScience, Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Abraxis BioScience, Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Abraxis BioScience, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Abraxis BioScience, Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Abraxis BioScience, Inc. and identify potential opportunities in those areas.
Abraxis BioScience, Inc. Snapshot
Abraxis BioScience, Inc. Overview
Key Information
Key Facts
Abraxis BioScience, Inc. – Research and Development Overview
Key Therapeutic Areas
Abraxis BioScience, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Abraxis BioScience, Inc. – Pipeline Products Glance
Abraxis BioScience, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Abraxis BioScience, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Abraxis BioScience, Inc. – Drug Profiles
Abraxane
  Product Description
  Mechanism of Action
  R&D Progress
Abraxane + Carboplatin
  Product Description
  Mechanism of Action
  R&D Progress
Abraxane + Gemzar
  Product Description
  Mechanism of Action
  R&D Progress
ABI-008
  Product Description
  Mechanism of Action
  R&D Progress
Abraxane
  Product Description
  Mechanism of Action
  R&D Progress
Abraxane + Avastin
  Product Description
  Mechanism of Action
  R&D Progress
Abraxane + Carboplatin + Herceptin
  Product Description
  Mechanism of Action
  R&D Progress
Abraxane + Genasense + Temodar
  Product Description
  Mechanism of Action
  R&D Progress
Adriamycin + Cytoxan + Taxol + Bevacizumab
  Product Description
  Mechanism of Action
  R&D Progress
Cytoxan + Neulasta + Bevacizumab + Adriamycin + Abraxane
  Product Description
  Mechanism of Action
  R&D Progress
ABI-009
  Product Description
  Mechanism of Action
  R&D Progress
ABI-010
  Product Description
  Mechanism of Action
  R&D Progress
ABI-010 + ABI-007
  Product Description
  Mechanism of Action
  R&D Progress
ABI-011
  Product Description
  Mechanism of Action
  R&D Progress
Abraxis BioScience, Inc. – Pipeline Analysis
Abraxis BioScience, Inc. – Pipeline Products by Therapeutic Class
Abraxis BioScience, Inc. Pipeline Products By Target
Abraxis BioScience, Inc. – Pipeline Products by Route of Administration
Abraxis BioScience, Inc. – Pipeline Products by Molecule Type
Abraxis BioScience, Inc. – Recent Pipeline Updates
Abraxis BioScience, Inc. - Dormant Projects
Abraxis BioScience, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
ABI-008
Abraxane + Carboplatin
Abraxane + Carboplatin + Radiation Therapy
Abraxane + Vinorelbine
Abraxane + Vinorelbine + G-CSF
Abraxis BioScience, Inc. – Company Statement
Abraxis BioScience, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Apr 18, 2010: ABRAXANE In Combination With Gemcitabine Increases Survival In First-Line Treatment Of Advanced Pancreatic Cancer In Phase I/II Study
Apr 08, 2010: Abraxis To Present Phase I/II Pancreatic Survival Data At 101st Annual Meeting Of American Association For Cancer Research
Financial Deals Landscape
Abraxis BioScience, Inc., Deals Volume Summary, 2004 to YTD 2011
Abraxis BioScience, Inc., Deals Summary By Region, 2004 to YTD 2011
Abraxis BioScience, Inc., Deals Summary, 2004 to YTD 2011
Abraxis BioScience, Inc. Detailed Deal Summary
Asset Purchase
Abraxis BioScience Re-Acquires ABRAXANE From AstraZeneca
Acquisition
Abraxis BioScience Acquires Shimoda Biotech And Platco Technologies
Venture Financing
Expression Pathology Secures $6.5 Million In Financing From Abraxis BioScience
Equity Offering
ProMetic Completes Private Placement Of $7 Million
Abraxis BioScience Files Shelf Registration Statement For $400 Million
ProMetic Life Sciences Enters Into Co-Development Agreement With Abraxis BioScience
Abraxis BioScience And AstraZeneca Enters Into Research Agreement With NCCN
Abraxis BioScience Enters Into Research Collaboration With California NanoSystems Institute
Abraxis BioScience Forms Joint Venture With Cenomed
Abraxis BioScience Enters Into Co-Promotion Agreement With AstraZeneca
Abraxis BioScience Terminates Co-Promotion Agreement With AstraZeneca
Licensing Agreements
Abraxis Enters Into License Agreement With ProMetic Life Sciences
Abraxis Bioscience Enters Into License Agreement With Green Cross
Green Cross Enters Into An Licensing Agreement With Abraxis BioScience
Abraxis BioScience Enters Into Licensing Agreement With The Scripps Research Institute
Abraxis BioScience Enters Into Licensing Agreement With Biocon
Abraxis BioScience Enters Into License Agreement With The Buck Institute
Abraxis BioScience Enters Into Licensing Agreement With Biocon
Abraxis BioScience Enters Into License Agreement With University Of Southern California
Abraxis BioScience Enters Into Licensing Agreement With University of Maryland
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 81

LIST OF TABLES

Abraxis BioScience, Inc. – Pipeline by Therapy Area and Indication, 2010
Abraxis BioScience, Inc. – Pipeline by Stage of Development, 2010
Abraxis BioScience, Inc. – Monotherapy Products in Pipeline, 2010
Abraxis BioScience, Inc. – Combination Treatment Modalities in Pipeline, 2010
Abraxis BioScience, Inc. – Phase III, 2010
Abraxis BioScience, Inc. - Phase II, 2010
Abraxis BioScience, Inc. - Phase I, 2010
Abraxis BioScience, Inc. - Pipeline By Therapeutic Class, 2010
Abraxis BioScience, Inc. - Pipeline By Target, 2010
Abraxis BioScience, Inc. – Pipeline By Route of Administration, 2010
Abraxis BioScience, Inc. – Pipeline By Molecule Type, 2010
Abraxis BioScience, Inc. – Recent Pipeline Updates, 2010
Abraxis BioScience, Inc. - Dormant Developmental Projects, 2010
Abraxis BioScience, Inc. - Discontinued Pipeline Products, 2010
Abraxis BioScience, Inc., Other Locations
Abraxis BioScience, Inc., Subsidiaries
Abraxis BioScience, Inc., Deals Summary, 2004 to YTD 2011
Abraxis BioScience, Inc., Deals Summary by Region, 2004 to YTD 2011
Abraxis BioScience, Inc., Deals Summary, 2004 to YTD 2011 53

LIST OF FIGURES

Abraxis BioScience, Inc. – Pipeline by Therapy Area and Indication, 2010
Abraxis BioScience, Inc. – Pipeline by Stage of Development, 2010
Abraxis BioScience, Inc. – Monotherapy Products in Pipeline, 2010
Abraxis BioScience, Inc. – Combination Treatment Modalities in Pipeline, 2010
Abraxis BioScience, Inc. – Pipeline By Therapeutic Class, 2010
Abraxis BioScience, Inc. - Pipeline By Target, 2010
Abraxis BioScience, Inc. – Pipeline By Route of Administration, 2010
Abraxis BioScience, Inc. – Pipeline By Molecule Type, 2010 39

Ask Your Question

Abraxis BioScience, Inc. – Product Pipeline Review – Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: